MX2007000892A - Un hidrato variable cristalino de la sal de (s)-3-piridincarboxami da, 6-[4-[2-[[3-(9h-carbazol-4-iloxi)-2-hidroxipropil]amino]-2-met ilpropil]fenoxi]-hemisuccinato. - Google Patents

Un hidrato variable cristalino de la sal de (s)-3-piridincarboxami da, 6-[4-[2-[[3-(9h-carbazol-4-iloxi)-2-hidroxipropil]amino]-2-met ilpropil]fenoxi]-hemisuccinato.

Info

Publication number
MX2007000892A
MX2007000892A MX2007000892A MX2007000892A MX2007000892A MX 2007000892 A MX2007000892 A MX 2007000892A MX 2007000892 A MX2007000892 A MX 2007000892A MX 2007000892 A MX2007000892 A MX 2007000892A MX 2007000892 A MX2007000892 A MX 2007000892A
Authority
MX
Mexico
Prior art keywords
carbazol
yloxy
methylpropyl
phenoxy
hydroxypropyl
Prior art date
Application number
MX2007000892A
Other languages
English (en)
Inventor
Julie Kay Bush
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2007000892A publication Critical patent/MX2007000892A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a un hidrato variable cristalino de (S)-3-piridincarboxamida, 6-[4-[2-[[3-(9H-carbazol-4-iloxi)-2- hidroxipropil]amino]-2-metilpropil]fenoxi])-hemi-succinato, una formulacion farmaceutica que contiene dicha sal y a metodos para tratar obesidad y/o diabetes Tipo 2 usando dicha sal (ver formula).
MX2007000892A 2004-07-22 2005-07-14 Un hidrato variable cristalino de la sal de (s)-3-piridincarboxami da, 6-[4-[2-[[3-(9h-carbazol-4-iloxi)-2-hidroxipropil]amino]-2-met ilpropil]fenoxi]-hemisuccinato. MX2007000892A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59025104P 2004-07-22 2004-07-22
PCT/US2005/024886 WO2006019835A1 (en) 2004-07-22 2005-07-14 A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinicarbox amide hemisuccinate salt

Publications (1)

Publication Number Publication Date
MX2007000892A true MX2007000892A (es) 2007-05-23

Family

ID=35106749

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007000892A MX2007000892A (es) 2004-07-22 2005-07-14 Un hidrato variable cristalino de la sal de (s)-3-piridincarboxami da, 6-[4-[2-[[3-(9h-carbazol-4-iloxi)-2-hidroxipropil]amino]-2-met ilpropil]fenoxi]-hemisuccinato.

Country Status (17)

Country Link
US (1) US7834187B2 (es)
EP (2) EP2233482A1 (es)
JP (1) JP4922163B2 (es)
CN (1) CN1989129B (es)
AT (1) ATE480534T1 (es)
AU (1) AU2005275185B2 (es)
BR (1) BRPI0513569A2 (es)
CA (1) CA2572631C (es)
CY (1) CY1110806T1 (es)
DE (1) DE602005023474D1 (es)
DK (1) DK1773811T3 (es)
ES (1) ES2349798T3 (es)
MX (1) MX2007000892A (es)
PL (1) PL1773811T3 (es)
PT (1) PT1773811E (es)
SI (1) SI1773811T1 (es)
WO (1) WO2006019835A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235919A (en) * 1977-07-21 1980-11-25 Sandoz Ltd. 1-(Indol-4-yloxy)-3-(2-substituted amino)-2-propanols and pharmaceutical use thereof
DE69711519T2 (de) * 1996-09-05 2002-10-31 Lilly Co Eli Carbazolanaloge als selektive beta3-adrenergische Agonisten
ATE251151T1 (de) * 1999-07-29 2003-10-15 Lilly Co Eli Eine kristalline form von 6-hydroxy-3-(4-(2- (piperidin-1-yl)ethoxy)phenoxy)-2-(4- methoxyphenyl)benzo(b)thiophen-hydrochlorid
AU6335600A (en) * 1999-07-29 2001-02-19 Eli Lilly And Company A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride
EA005116B1 (ru) * 2000-10-20 2004-10-28 Эли Лилли Энд Компани НОВАЯ КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ)БЕНЗО[b]ТИОФЕНА
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
CA2455050C (en) * 2001-08-15 2007-02-20 Pharmacia & Upjohn Company Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof

Also Published As

Publication number Publication date
CA2572631C (en) 2012-05-15
WO2006019835A1 (en) 2006-02-23
CN1989129B (zh) 2010-11-10
ES2349798T3 (es) 2011-01-11
EP1773811A1 (en) 2007-04-18
US20080058385A1 (en) 2008-03-06
PL1773811T3 (pl) 2011-02-28
CA2572631A1 (en) 2006-02-23
AU2005275185A1 (en) 2006-02-23
DK1773811T3 (da) 2010-12-13
CY1110806T1 (el) 2015-06-10
BRPI0513569A2 (pt) 2012-10-09
CN1989129A (zh) 2007-06-27
EP1773811B1 (en) 2010-09-08
EP2233482A1 (en) 2010-09-29
US7834187B2 (en) 2010-11-16
DE602005023474D1 (en) 2010-10-21
SI1773811T1 (sl) 2011-01-31
AU2005275185B2 (en) 2011-06-23
JP2008507519A (ja) 2008-03-13
ATE480534T1 (de) 2010-09-15
PT1773811E (pt) 2010-10-19
JP4922163B2 (ja) 2012-04-25

Similar Documents

Publication Publication Date Title
NZ594385A (en) Aminopyrimidines useful as kinase inhibitors
UA85686C2 (ru) Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}- 1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его применение как лекарственного средства, способ его получения
TW200637822A (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
HK1124048A1 (en) 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
TW200633981A (en) Process for the preparation of a 2-ethylaminopyridine derivative
MY149140A (en) Hydrates of 2-chloro 5-y3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoro-methyl)-1-(2h)-pyrimidinyl"-4-fluoro-n- yymethyl-(1-methylethyl)-amino"sulphonyl"benzamide
UA92354C2 (en) Amino acid salts of rosiglitazone
NZ700778A (en) Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{ 6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl} -1-methyl-urea and salts thereof.
DE60140581D1 (de) Pharmazeutische Zusammensetzungen beinhaltend Kristallsalze von 7-Ä4-(4-Fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ-(3R,5S)-3,5-dihydroxyhept-6-ensäure
UA92349C2 (ru) Полиморфы этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты
RS53600B1 (en) UNITS, PREPARATIONS AND METHODS
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
PE20060243A1 (es) Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina
UA85062C2 (uk) Кристалічна форма кальцію біс[(е)-7-[4-(4-флуорфеніл)-6-ізопропіл-2-[метил(метилсульфоніл)аміно]піримідин-5-іл](3r,5s)-3,5-дигідроксигепт-6-енової кислоти]
HK1041265A1 (en) Process for the production of tert-butyl(e)-(6-(2-(4-(4-fluorophenyl-6- isopropyl-2-(methyl(methylsulfonyl)amino)pyrimidin-5-yl)vinyl(4r,6s)-2,2- dimethyl(1,3)dioxan-4-yl)acetate
EP1533304A4 (en) AMIDE DERIVATIVE
EP2578574A4 (en) OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE AND PROCESS FOR PREPARING THE SAME
TW200700410A (en) Besylate salt of 7-(2-(4-(3-(trifluoromethyl)phenyl) -1,2,3,6-tetrahydropyrid-1-yl)ethyl) isoquinoline, its preparation and its use in therapeutics
TW200730507A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MX2007000892A (es) Un hidrato variable cristalino de la sal de (s)-3-piridincarboxami da, 6-[4-[2-[[3-(9h-carbazol-4-iloxi)-2-hidroxipropil]amino]-2-met ilpropil]fenoxi]-hemisuccinato.
ATE256678T1 (de) 4-(2-pyridyl)piperazine als agonisten des 5ht7 rezeptors
DK1565440T3 (da) Ny fremgangsmåde til fremstilling af 2-aminomethylpyridinderivater
AU2003235814A8 (en) Novel process for the preparation of trans-3- ethyl-2,5- dihydro-4- methyl-n-(2-( 4-(((((4-methyl cyclohexyl) amino)carbonyl) amino)sulfonyl) phenyl)ethyl) -2-oxo-1h-pyrrole -1-carboxamide
NO20053431D0 (no) Ny krystallinsk modifikasjon av 2-(3,5-bis-trifluormetyl-fenyl)-N-(6-(1,1-diokso-1gamma6-tiomorfolin-4-yl)-4(4-fluor-2-metyl-fenyl)-pyridin-3-yl)-N-metyl-isobutyramid.
DE602004022540D1 (de) Verwendung von tyrosin-kinase-hemmern zur behandlung von diabetes

Legal Events

Date Code Title Description
FG Grant or registration